These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 2083056)

  • 1. [The structure of distribution of pharmaceutical products in the countries of the EEC].
    Passerini F
    Boll Chim Farm; 1990 May; 129(5):199-209. PubMed ID: 2083056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Future European health care: cost containment, health care reform and scientific progress in drug research.
    Emilien G
    Int J Health Plann Manage; 1997; 12(2):81-101. PubMed ID: 10173136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. European prices of newly launched reimbursable pharmaceuticals--a pilot study.
    Martikainen J; Kivi I; Linnosmaa I
    Health Policy; 2005 Nov; 74(3):235-46. PubMed ID: 16226136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmaceutical price differences in the EU: investigation from cardiovascular disease drugs.
    Timur A; Picone G
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):251-6. PubMed ID: 19527097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
    Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
    Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The European Union and drugs].
    Viala G; Campion MD
    Ann Pharm Fr; 1995; 53(4):184-7. PubMed ID: 7574273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Coordination of industrial research of foodstuffs in the countries of the EEC and in other European countries associated with the EEC within the framework of COST].
    Vos G
    Ann Nutr Aliment; 1978; 32(2-3):689-97. PubMed ID: 707939
    [No Abstract]   [Full Text] [Related]  

  • 8. [How the EEC membership influences drug supply in Sweden].
    Lennholm B
    Lakartidningen; 1995 Feb; 92(6):491-3. PubMed ID: 7853924
    [No Abstract]   [Full Text] [Related]  

  • 9. [An interview with Dr. D. Poggiolini, director of the Pharmaceutical Service of the Health Ministry and the Drug Committee of the EEC. Interview by Giuseppe Lojacono].
    Poggiolini D
    Epidemiol Prev; 1988 Dec; 10(37):9. PubMed ID: 2978859
    [No Abstract]   [Full Text] [Related]  

  • 10. [Guiding principles for industrial policy in the pharmaceutical sector of the European Community. European Economic Community].
    Neri M; Palazzo S
    Boll Chim Farm; 1996 Nov; 135(10):575-9. PubMed ID: 9081293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative approaches to pharmaceutical price regulation in the European Union.
    Mrazek MF
    Croat Med J; 2002 Aug; 43(4):453-61. PubMed ID: 12187524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The EEC creates a European Medical Product Agency].
    Johnson K
    Lakartidningen; 1993 Oct; 90(40):3395. PubMed ID: 8231477
    [No Abstract]   [Full Text] [Related]  

  • 13. Analysis of the pharmaceuticals market and its technological development in Turkey.
    Kisa A
    Int J Technol Assess Health Care; 2006; 22(4):537-42. PubMed ID: 16984690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Drug control within the EEC II: good possibilities for Sweden].
    Strandberg K
    Lakartidningen; 1992 Jan; 89(4):178-9. PubMed ID: 1734147
    [No Abstract]   [Full Text] [Related]  

  • 15. Biotech patents-business as usual?
    Lawrence S
    Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861
    [No Abstract]   [Full Text] [Related]  

  • 16. Redesigner drugs.
    Dove A
    Nat Biotechnol; 2004 Aug; 22(8):953-7. PubMed ID: 15286643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Status of the GCP guidelines in Europe.
    Geussenhainer S
    Methods Find Exp Clin Pharmacol; 1993 May; 15(4):223-8. PubMed ID: 8361259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excellence in education and training advances competitiveness of the pharmaceutical industry in Europe.
    Bjerrum OJ
    Eur J Pharm Sci; 2011 Sep; 44(1-2):174-5. PubMed ID: 21782938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Safety assessment of new products developed by the pharmaceutical industry].
    Claude JR
    Ann Pharm Fr; 2001 Sep; 59(5):324-30. PubMed ID: 11787426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness data on biologics needed.
    Sheridan C; Katsnelson A
    Nat Biotechnol; 2005 Mar; 23(3):272-3. PubMed ID: 15765069
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.